Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7150)	9/3/1998 9:47:00 AM
From: Thomas J Pittman	Respond to of 17367

Lots of stress showing here as well recognize that our cards are all on the table and we await the ruling from the feds. I have actually exited most of my stock positions as of about 2 weeks ago (pure luck that I missed the big selloff, no real skill on my part) except for XOMA. I am sticking this one out. I figure by December I will either have my first stock go worthless or have a smug look and be trying decide whether to stick with it for the next 10 years. It is exciting. Deep breath, sit back and wait. OK. I'm ready. J

To: aknahow who wrote (7150)	9/3/1998 12:55:00 PM
From: Robert K.	Respond to of 17367

According to the company FAQ's >The original Phase III design agreed to by the FDA called for a two year trial. Our intention was (and is) to accrue as many patients as we can in two years. At the time we started the trial, with only US data, getting to 200 patients seemed very unlikely. With the addition of UK sites, if current accrual keeps up, we will have data from well over 200 patients within the 2 years. The larger the sample size, the more reliable the statistical analysis will be< My read is the trial goal was 200 and/or 2 years. Well we got the 200. So does the FDA want 2 years or does xoma (for more power)? I guess the dsmb might indeed halt at 200 if it shows a good enough result. Its possible it may not need a outstanding result. Pure speculation on my part.